Schedule of basic and diluted loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
2016
|
|
2015
|
|
2014
|
|
|
|
|
(in thousands, except share and per share data)
|
|
Net (loss) income, basic
|
|
$
|
(102,978)
|
|
$
|
(37,783)
|
|
$
|
19,675
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrants liability
|
|
|
(4,744)
|
|
|
—
|
|
|
—
|
|
Net loss, diluted
|
|
$
|
(107,722)
|
|
$
|
(37,783)
|
|
$
|
19,675
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in calculating basic net loss per common share
|
|
|
61,830,967
|
|
|
32,589,795
|
|
|
31,359,867
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive stock options
|
|
|
—
|
|
|
—
|
|
|
1,450,720
|
|
Warrants to purchase common shares - liability-classified
|
|
|
52,049
|
|
|
—
|
|
|
—
|
|
Shares used in calculating diluted net loss per common share
|
|
|
61,883,016
|
|
|
32,589,795
|
|
|
32,810,587
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per common share, basic
|
|
$
|
(1.67)
|
|
$
|
(1.16)
|
|
$
|
0.63
|
|
Net (loss) income per common share, diluted
|
|
$
|
(1.74)
|
|
$
|
(1.16)
|
|
$
|
0.60
|
|
|
Potential common shares excluded from the calculation of diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
2016
|
|
2015
|
|
2014
|
|
|
|
|
|
|
|
|
|
Options to purchase common shares, RSUs and PSUs
|
|
7,388,888
|
|
—
|
|
—
|
|
Warrants to purchase common shares - equity-classified
|
|
92,223
|
|
—
|
|
—
|
|
2022 Notes convertible into common shares
|
|
8,190,534
|
|
—
|
|
—
|
|
|
Summary of warrants outstanding and exercisable |
|
|
|
|
|
|
|
|
No. of Warrants
|
|
Weighted-Average
|
Quarterly period of expiration
|
|
Outstanding
|
|
Exercise Price
|
Q2 2017
|
|
46,497
|
|
$
|
4.71
|
Q1 2018
|
|
599,278
|
|
|
4.12
|
Q3 2018
|
|
15,815
|
|
|
3.78
|
Q4 2019
|
|
107,670
|
|
|
4.81
|
Q3 2020
|
|
109,968
|
|
|
4.09
|
Q1 2021
|
|
50,521
|
|
|
2.91
|
|
|
929,749
|
|
$
|
4.16
|
|